{"id":"https://openalex.org/W1965157100","doi":"https://doi.org/10.1371/journal.pone.0089105","title":"In-Depth Analysis Shows Synergy between Erlotinib and miR-34a","display_name":"In-Depth Analysis Shows Synergy between Erlotinib and miR-34a","publication_year":2014,"publication_date":"2014-02-14","ids":{"openalex":"https://openalex.org/W1965157100","doi":"https://doi.org/10.1371/journal.pone.0089105","mag":"1965157100","pmid":"https://pubmed.ncbi.nlm.nih.gov/24551227","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3925231"},"language":"en","primary_location":{"id":"doi:10.1371/journal.pone.0089105","doi":"https://doi.org/10.1371/journal.pone.0089105","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0089105","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089105&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089105&type=printable","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024978408","display_name":"Jane Y. Zhao","orcid":"https://orcid.org/0000-0003-1664-2035","observed_orcids":["https://orcid.org/0000-0003-1664-2035"]},"institutions":[{"id":"https://openalex.org/I4210122992","display_name":"Mirna Therapeutics (United States)","ror":"https://ror.org/02tdag098","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jane Zhao","raw_affiliation_strings":["Mirna Therapeutics, Inc., Austin, Texas, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mirna Therapeutics, Inc., Austin, Texas, United States of America","institution_ids":["https://openalex.org/I4210122992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108621795","display_name":"Kevin Kelnar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122992","display_name":"Mirna Therapeutics (United States)","ror":"https://ror.org/02tdag098","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Kelnar","raw_affiliation_strings":["Mirna Therapeutics, Inc., Austin, Texas, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mirna Therapeutics, Inc., Austin, Texas, United States of America","institution_ids":["https://openalex.org/I4210122992"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086967072","display_name":"Andreas G. Bader","orcid":"https://orcid.org/0009-0001-6301-9492","observed_orcids":["https://orcid.org/0009-0001-6301-9492"]},"institutions":[{"id":"https://openalex.org/I4210122992","display_name":"Mirna Therapeutics (United States)","ror":"https://ror.org/02tdag098","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122992"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andreas G. Bader","raw_affiliation_strings":["Mirna Therapeutics, Inc., Austin, Texas, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mirna Therapeutics, Inc., Austin, Texas, United States of America","institution_ids":["https://openalex.org/I4210122992"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5086967072"],"corresponding_institution_ids":["https://openalex.org/I4210122992"],"apc_list":{"value":2382,"currency":"USD","value_usd":2382},"apc_paid":{"value":2382,"currency":"USD","value_usd":2382},"fwci":3.9487,"has_fulltext":true,"cited_by_count":67,"citation_normalized_percentile":{"value":0.94769262,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":90,"max":100},"biblio":{"volume":"9","issue":"2","first_page":"e89105","last_page":"e89105"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10062","display_name":"MicroRNA in disease regulation","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10062","display_name":"MicroRNA in disease regulation","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.007899999618530273,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10515","display_name":"Cancer-related molecular mechanisms research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/mir-34a","display_name":"miR-34a","score":0.996999979019165},{"id":"https://openalex.org/keywords/microrna-mimics","display_name":"miRNA mimics","score":0.7570000290870667},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8119999766349792},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors","display_name":"epidermal growth factor receptor tyrosine kinase inhibitors","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7509999871253967},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8650000095367432},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/tumor-suppressor-microrna","display_name":"tumor suppressor microRNA","score":0.6880000233650208},{"id":"https://openalex.org/keywords/cancer-cell-proliferation-inhibition","display_name":"cancer cell proliferation inhibition","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9930520057678223},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6082403063774109},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.5940074324607849},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5888115167617798},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5558576583862305},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5426663756370544},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.537472665309906},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4595661461353302},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45448872447013855},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4471384882926941},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.431233286857605},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3746986389160156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30504536628723145}],"mesh":[{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D035683","descriptor_name":"MicroRNAs","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":7,"locations":[{"id":"doi:10.1371/journal.pone.0089105","doi":"https://doi.org/10.1371/journal.pone.0089105","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0089105","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089105&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2910206","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3925231","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3925231","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3925231","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS One","raw_type":"Text"},{"id":"pmid:24551227","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24551227","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PloS one","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.770.7495","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.770.7495","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/42/8d/pone.0089105.PMC3925231.pdf","raw_type":"text"},{"id":"pmh:oai:doaj.org/article:49398035df444dae9e0185715ff99f76","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/49398035df444dae9e0185715ff99f76","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PLoS ONE, Vol 9, Iss 2, p e89105 (2014)","raw_type":"article"},{"id":"pmh:oai:figshare.com:article/936058","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/_In_Depth_Analysis_Shows_Synergy_between_Erlotinib_and_miR_34a_/936058","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"}],"best_oa_location":{"id":"doi:10.1371/journal.pone.0089105","doi":"https://doi.org/10.1371/journal.pone.0089105","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0089105","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089105&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4376718758","display_name":"Combination molecular therapeutics for lung cancer","funder_award_id":"R43CA134071","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6376881785","display_name":"MicroRNA therapeutics for prostate cancer","funder_award_id":"R43CA137939","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320308129","display_name":"Cancer Prevention and Research Institute of Texas","ror":"https://ror.org/0003xa228"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1965157100.pdf","grobid_xml":"https://content.openalex.org/works/W1965157100.grobid-xml"},"referenced_works_count":44,"referenced_works":["https://openalex.org/W1967394241","https://openalex.org/W1972019750","https://openalex.org/W1976779081","https://openalex.org/W1983774108","https://openalex.org/W1988337994","https://openalex.org/W1998971866","https://openalex.org/W2002937040","https://openalex.org/W2007661090","https://openalex.org/W2013073866","https://openalex.org/W2014187999","https://openalex.org/W2018056175","https://openalex.org/W2068244265","https://openalex.org/W2074766088","https://openalex.org/W2078071018","https://openalex.org/W2094532696","https://openalex.org/W2096439168","https://openalex.org/W2102627944","https://openalex.org/W2103004313","https://openalex.org/W2106036268","https://openalex.org/W2106391833","https://openalex.org/W2111129864","https://openalex.org/W2111264921","https://openalex.org/W2115497785","https://openalex.org/W2118135682","https://openalex.org/W2120181506","https://openalex.org/W2121389354","https://openalex.org/W2123555204","https://openalex.org/W2133488997","https://openalex.org/W2138343959","https://openalex.org/W2140477106","https://openalex.org/W2141738919","https://openalex.org/W2144154026","https://openalex.org/W2146404049","https://openalex.org/W2150079073","https://openalex.org/W2158811981","https://openalex.org/W2162724777","https://openalex.org/W2163169932","https://openalex.org/W2167620731","https://openalex.org/W2169105660","https://openalex.org/W2170685293","https://openalex.org/W2206860290","https://openalex.org/W2236524872","https://openalex.org/W2999447345","https://openalex.org/W7073924416"],"related_works":["https://openalex.org/W2591748786","https://openalex.org/W2498329006","https://openalex.org/W2477416155","https://openalex.org/W1549139917","https://openalex.org/W2165295475","https://openalex.org/W2560756229","https://openalex.org/W2792645723","https://openalex.org/W3164944461","https://openalex.org/W2043133404","https://openalex.org/W3036095792"],"abstract_inverted_index":{"Tyrosine":[0],"kinase":[1],"inhibitors":[2],"directed":[3],"against":[4],"epidermal":[5],"growth":[6,47],"factor":[7],"receptor":[8],"(EGFR-TKI),":[9],"such":[10],"as":[11],"erlotinib,":[12],"are":[13],"effective":[14],"in":[15,80,95,143,232],"a":[16,96,103,134,152,184,212,235],"limited":[17],"fraction":[18],"of":[19,28,68,77,98,118,154,187,205,214],"non-small":[20],"cell":[21,120,189],"lung":[22],"cancer":[23,32,104,119,145,188],"(NSCLC).":[24],"However,":[25],"the":[26,66,74,78,192,198,228],"majority":[27,213],"NSCLC":[29,81,215],"and":[30,70,72,85,140,158,167,173,216],"other":[31,217],"types":[33],"remain":[34],"resistant.":[35],"Therapeutic":[36],"miRNA":[37],"mimics":[38,142],"modeled":[39],"after":[40],"endogenous":[41],"tumor":[42,46],"suppressor":[43],"miRNAs":[44],"inhibit":[45],"by":[48,169,197],"repressing":[49],"multiple":[50,113],"oncogenes":[51],"at":[52,180],"once":[53],"and,":[54,202],"therefore,":[55],"may":[56,224],"be":[57,108],"used":[58,231],"to":[59,107,110,124,171,227],"augment":[60],"drug":[61,90,159,229],"sensitivity.":[62],"Here,":[63],"we":[64],"investigated":[65],"relationship":[67],"miR-34a":[69,141,168],"erlotinib":[71,87,139,166,223],"determined":[73,123],"therapeutic":[75],"activity":[76],"combination":[79,91,233],"cells":[82,101,146],"with":[83,234],"primary":[84],"acquired":[86],"resistance.":[88],"The":[89,208],"was":[92,122,149,178],"also":[93],"tested":[94],"panel":[97],"hepatocellular":[99],"carcinoma":[100],"(HCC),":[102],"type":[105],"known":[106],"refractory":[109],"erlotinib.":[111],"Using":[112],"analytical":[114],"approaches,":[115],"drug-induced":[116],"inhibition":[117,190],"proliferation":[121],"reveal":[125],"additive,":[126],"antagonistic":[127],"or":[128],"synergistic":[129,136],"effects.":[130],"Our":[131],"data":[132,209],"show":[133],"strong":[135],"interaction":[137],"between":[138],"all":[144],"tested.":[147],"Synergy":[148],"observed":[150],"across":[151],"range":[153],"different":[155],"dose":[156,163],"levels":[157],"ratios,":[160],"reducing":[161],"IC50":[162],"requirements":[164],"for":[165,222],"up":[170],"46-fold":[172],"13-fold,":[174],"respectively.":[175],"Maximal":[176],"synergy":[177],"detected":[179],"dosages":[181],"that":[182,194,211],"provide":[183],"high":[185],"level":[186],"beyond":[191],"one":[193],"is":[195,204],"induced":[196],"single":[199],"agents":[200],"alone":[201],"thus,":[203],"clinical":[206],"relevance.":[207],"suggest":[210],"cancers":[218],"previously":[219],"not":[220],"suited":[221],"prove":[225],"sensitive":[226],"when":[230],"miR-34a-based":[236],"therapy.":[237]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}